Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is a single arm open-label multicenter phase I/II investigation of combination
lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma.
This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS
lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory
imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that
Tafasitamab enhances blood-brain barrier permeability, a potential property that could have
broad clinical implications.